Trials / Completed
CompletedNCT00333866
Randomized, Double-Blind, Placebo-Controlled Trial Of Pregabalin In Patients With Fibromyalgia.
A 14 Week, Randomized, Double-Blind, Placebo-Controlled Trial Of Pregabalin Twice Daily In Patients With Fibromyalgia.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 747 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study, will compare pregabalin with placebo for the duration of 14 weeks to evaluate the efficacy and safety of pregabalin in patients with fibromyalgia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pregabalin | 600mg/day |
| DRUG | pregabalin | 450mg/day |
| DRUG | pregabalin | 300mg/day |
| DRUG | placebo | placebo |
Timeline
- Start date
- 2006-07-01
- Primary completion
- 2007-11-01
- Completion
- 2007-11-01
- First posted
- 2006-06-06
- Last updated
- 2021-02-11
- Results posted
- 2009-05-13
Locations
74 sites across 16 countries: Australia, Canada, Denmark, France, Germany, India, Italy, Mexico, Netherlands, Portugal, South Korea, Spain, Sweden, Switzerland, United Kingdom, Venezuela
Source: ClinicalTrials.gov record NCT00333866. Inclusion in this directory is not an endorsement.